Latin America Therapeutic Vaccines Market which is poised to reach $361.06 Million in 2023, from the current value of $1618.98 Million in 2018 with a CAGR of 35% Currently, in pipeline several approaches are being developed in order to boost the immune response to various infectious and cancerous cells. There are presently close to 120 new vaccines in the pipeline of various multinational companies across the globe set to hit the market in the next few years. Added to this the vaccine market is rather concentrated on both supply and demand sides. It is highly regulated and mostly dependent on public purchasers and donor policies. It has very distinct features which increase the complexity of assessing and understanding pricing and procurement in their context.
Coming to Latin America Sanofi Pasteur, the vaccines division of Sanofi, announced that Brazil has granted regulatory approval to Dengvaxia®, representing the third successful licensure of the dengue vaccine, which was also approved in Mexico and the Philippines earlier in 2015. This in the light of the fact that Brazil being the fifth most populated in world and first in Latin America is plagued by 1.4 million dengue patients. The remaining countries in Latin America also have a natural threat as they lie in the tropical amazon basin which makes them a hotbed for various epidemics.
Increase in funding’s from government for vaccine development, rise in investments by the major market players, rising prevalence of disease, technological advancements, initiatives by NGO’s are some of the factors that are propelling the market growth. However, massive capital expenditures and stringent regulatory policies, high cost associated with treatment are few factors inhibiting the growth of the market.
By types of disease, the Latin America Therapeutic Vaccines Market is segmented into Autoimmune Disease Vaccines (Type I Diabetes), Cancer Vaccines (Multikine, PR1 Peptide Vaccine, TroVax, CYT004-MelQbG10 etc.), Neurological Disease Vaccines (ACC-001, CAD106, Parkinson’s Disease Vaccine, Alzheimer's Disease and Other Disease Vaccines), and Infectious Disease Vaccines (Hepatitis C, HIV/AIDS and Other Infectious Disease Vaccines). Furthermore, on the basis of geography, it is segmented and analysed at a country level including Brazil, Argentina and Mexico.
Some of the key industry leaders that have been operating in Latin America are GlaxoSmithKline, plc., Merck and Company, Bavarian Nordic, CSL Limited, Emergent BioSolutions Inc., Novartis AG, Johnson and Johnson, MedImmune, LLC, Pfizer, Inc., and Sanofi Pasteur.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.1 Introduction
2.2 Analysis Design
2.3 Research Phases
2.3.1 Secondary Research
2.3.2 Primary Research
2.3.3 Econometric Modelling
2.3.4 Expert Validation
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 By Disease Type
5.1.1 Autoimmune Disease Vaccines
5.1.2 Cancer Vaccines
5.1.2.1 Multikine
5.1.2.2 PR1 Peptide
5.1.2.3 TroVax
5.1.2.4 CYT004-MelQbG10
5.1.3 Neurological Disease Vaccines
5.1.3.1 ACC- 001
5.1.3.2 CAD 106
5.1.3.3 Parkinson's Disease Vaccine
5.1.3.4 Alzheimer's Disease
5.1.4 Infectious Disease Vaccines
5.1.4.1 Hepatitis C
5.1.4.2 HIV/AIDS
5.1.4.3 Other Infectious Disease
6.1 Introduction
6.2 Brazil
6.3 Argentina
6.4 Mexico
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.1 GlaxoSMithKline plc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Merck and Company
8.3 Bavarian Nordic
8.4 CSL Limited
8.5 Emergent Biosolutions Inc.
8.6 Novartis AG
8.7 Johnson and Johnson
8.8 MedImmune LLC
8.9 Pfizer Inc.
8.10 Sanofi Pasteur
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
